| Literature DB >> 33951307 |
Peng Liu1, Hai Nie1, Zhuan Wang1, Bao Yao1, Jia-Hong Li1, Ji Zhou1.
Abstract
OBJECTIVE: The concept of enhanced recovery after surgery (ERAS) has been proposed to provide guidance for the improved postoperative rehabilitation of patients with occipitocervical region disease (ORD).Entities:
Keywords: Atlanto-occipital joint; Enhanced recovery after surgery; Neck pain; Postoperative complications
Year: 2021 PMID: 33951307 PMCID: PMC8274187 DOI: 10.1111/os.13018
Source DB: PubMed Journal: Orthop Surg ISSN: 1757-7853 Impact factor: 2.071
Patient management methods during perioperative period
| Groups | Preoperative | Intraoperative | Postoperative |
|---|---|---|---|
| Traditional group ( | Traditional preoperative preparation | Traditional surgery |
Prevention of thrombosis and pneumonia Functional training |
| Ameliorated group ( | Traditional preoperative preparation |
Control of body temperature and blood pressure Navigation and minimal invasive surgery*** Bone tissue engineering**** Dura patch***** Electrophysiological monitoring Local anesthesia and hemostatic drugs****** |
Prevention of thrombosis and pneumonia Functional training |
| ERAS group ( |
Strengthen preoperative education Shorten fasting time* Preemptive analgesia** |
Control of body temperature and blood pressure Navigation and minimal invasive surgery*** Bone tissue engineering**** Dura patch***** Electrophysiological monitoring Local anesthesia and hemostatic drugs****** |
Prevention of thrombosis, pneumonia, nausea and vomiting Functional training Ladder for analgesia Assisted sedation Promoting sleep Promoting hematopoiesis and nutritional support |
*Preoperative fasting time was shortened to 2 hours through use of feeding nutrient solution
**Oral celecoxib was administered 2 days before surgery
***Application in cases in which pedicle screws were used
****Application in cases of bone grafts
*****Application in cases of operation involving the spinal canal, or within the skull
******tranexamic acid and ropivacaine were utilized in the wound cavity and subcutaneously.
Demographic data for occipitocervical region disease (ORD) patients
| Groups | Years | Gender (cases) | BMI (kg/m2) | ASA grade (cases) | |||
|---|---|---|---|---|---|---|---|
| Male | Female | I | II | III | |||
| Traditional group ( | 40.67 ± 11.43 | 40 | 33 | 22.24 ± 3.19 | 40 | 29 | 4 |
| Ameliorated group ( | 42.53 ± 11.84 | 37 | 33 | 22.42 ± 4.25 | 34 | 30 | 6 |
| ERAS group ( | 39.29 ± 9.72 | 39 | 26 | 21.94 ± 2.70 | 37 | 22 | 6 |
| χ2/ | 1.457 | 0.740 | 0.325 | 1.939 | |||
|
| 0.235 | 0.691 | 0.723 | 0.747 | |||
The characteristic and site of lesion
| Groups | Characteristic of lesion | Site of lesion | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Fracture | Dislocation | Tumor | Hemorrhages | Deformity | Instability | Occipital bone | Occipital bone and atlas | Atlas and/or axis | |
| Traditional group ( | 19 (26.03%) | 3 (4.11%) | 20 (27.40%) | 4 (5.48%) | 24 (32.88%) | 3 (4.11%) | 20 (27.40%) | 31 (42.47%) | 22 (30.14%) |
| Ameliorated group ( | 29 (41.43%) | 3 (4.29%) | 8 (11.43%) | 6 (8.57%) | 22 (31.43%) | 2 (2.86%) | 20 (28.57%) | 29 (41.43%) | 21 (30.00%) |
| ERAS group ( | 21 (32.31%) | 6 (9.23%) | 10 (15.38%) | 3 (4.62%) | 22 (33.85%) | 3 (4.62%) | 15 (23.08%) | 28 (43.08%) | 22 (33.85%) |
| χ2 | 11.264 | 0.650 | |||||||
|
| 0.337 | 0.957 | |||||||
Surgery‐relevant and hospitalization data for occipitocervical region disease (ORD) patients
| Variable | Traditional group ( | Ameliorated group ( | ERAS group ( | χ2/ |
| |
|---|---|---|---|---|---|---|
| Surgery and hospitalization (mean ± SD) | Surgery time(min) | 179.95 ± 45.37 | 184.62 ± 66.08 | 169.28 ± 42.26 | 1.503 | 0.225 |
| Blood loss (mL) | 1004.20 ± 217.91 | 940.51 ± 246.84 | 939.42 ± 239.32 | 1.774 | 0.172 | |
| Postoperative hospitalization (day) | 17.39 ± 3.37 | 16.20 ± 3.56 | 14.36 ± 2.57 | 15.41 | 0.000 *** | |
| Postoperative cost (RMB) | 19387.60 ± 4076.32 | 18017.33 ± 3288.02 | 17962.48 ± 2525.35 | 4.035 | 0.019* | |
| Change after surgery (mean ± SD) | Hemoglobin (g/L) | 23.25 ± 10.83 | 21.02 ± 10.13 | 20.20 ± 12.74 | 1.376 | 0.255 |
| Albumin (g/L) | 9.41 ± 4.81 | 8.03 ± 4.95 | 8.46 ± 3.63 | 1.740 | 0.178 | |
| Improvement of VAS score | 2.34 ± 1.47 | 2.57 ± 1.21 | 3.54 ± 1.54 | 13.603 | 0.000*** | |
| Perioperative complications | Cerebrospinal fluid leakage | 6 (8.22%) | 5 (7.14%) | 2 (3.08%) | 6.302 | 0.043 * |
| Wound complication | 7 (9.59%) | 3 (4.29%) | 2 (3.08%) | |||
| Another organ infection | 5 (6.85%) | 5 (7.14) | 4 (6.15%) | |||
| Nausea and vomiting | 11 (15.07%) | 9 (12.86) | 5 (7.69%) | |||
| Readmission | Rate | 2 (2.74%) | 3 (4.29%) | 2 (3.08%) | 0.287 | 0.866 |
*p < 0.05, ***p < 0.001